A real-world observation of antipsychotic effects on brain volumes and intrinsic brain activity in schizophrenia

Yifan Chen
The First Affiliated Hospital of China Medical University

Fay Y Womer
Washington University School of Medicine in St. Louis

Ruiqi Feng
The First Affiliated Hospital of China Medical University

Xizhe Zhang
Nanjing Medical University

Yanbo Zhang
Nanjing Medical University

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Please let us know how this document benefits you.

Recommended Citation
Chen, Yifan; Womer, Fay Y; Feng, Ruiqi; Zhang, Xizhe; Zhang, Yanbo; Duan, Jia; Chang, Miao; Yin, Zhiyang; Jiang, Xiaowei; Wei, Shengnan; Wei, Yange; Tang, Yanqing; and Wang, Fei, "A real-world observation of antipsychotic effects on brain volumes and intrinsic brain activity in schizophrenia." Frontiers in Neuroscience. 15, 749316 (2021).
https://digitalcommons.wustl.edu/open_access_pubs/11588

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Authors
Yifan Chen, Fay Y Womer, Ruiqi Feng, Xizhe Zhang, Yanbo Zhang, Jia Duan, Miao Chang, Zhiyang Yin, Xiaowei Jiang, Shengnan Wei, Yange Wei, Yanqing Tang, and Fei Wang
A Real-World Observation of Antipsychotic Effects on Brain Volumes and Intrinsic Brain Activity in Schizophrenia

Yifan Chen1,2,3, Fay Y. Womer4, Ruiqi Feng1,5, Xizhe Zhang2,6, Yanbo Zhang7, Jia Duan1,2,3, Miao Chang1,5, Zhiyang Yin1, Xiaowei Jiang1, Shengnan Wei1, Yange Wei1,2,3, Yanqing Tang1* and Fei Wang1,2,3*

1 Department of Psychiatry, The First Affiliated Hospital of China Medical University, Shenyang, China, 2 Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, China, 3 Department of Radiology, The First Affiliated Hospital of China Medical University, Shenyang, China, 4 Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, United States, 5 School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, China, 6 Nanjing Brain Hospital, Nanjing Medical University, Nanjing, China, 7 Functional Brain Imaging Institute of Nanjing Medical University, Nanjing, China

Background: The confounding effects of antipsychotics that led to the inconsistencies of neuroimaging findings have long been the barriers to understanding the pathophysiology of schizophrenia (SZ). Although it is widely accepted that antipsychotics can alleviate psychotic symptoms during the early most acute phase, the longer-term effects of antipsychotics on the brain have been unclear. This study aims to look at the susceptibility of different imaging measures to longer-term medicated status through real-world observation.

Methods: We compared gray matter volume (GMV) with amplitude of low-frequency fluctuations (ALFFs) in 89 medicated schizophrenia (med-SZ), 81 unmedicated schizophrenia (unmed-SZ), and 235 healthy controls (HC), and the differences were explored for relationships between imaging modalities and clinical variables. We also analyzed age-related effects on GMV and ALFF values in the two patient groups (med-SZ and unmed-SZ).

Results: Med-SZ demonstrated less GMV in the prefrontal cortex, temporal lobe, cingulate gyri, and left insula than unmed-SZ and HC (p < 0.05, family-wise error corrected). Additionally, GMV loss correlated with psychiatric symptom relief in all SZ. However, medicated status did not influence ALFF values: all SZ showed increased ALFF in the anterior cerebrum and decreased ALFF in posterior visual cortices compared with HC (p < 0.05, family-wise error corrected). Age-related GMV effects were seen in all regions, which showed group-level differences except fusiform gyrus. No significant correlation was found between ALFF values and psychiatric symptoms.
Chen et al. A Real-World Observation
the human brain. 
serves as a structural substrate for the intrinsic brain activity of 
size/volume and intrinsic brain activity, suggesting that brain 
direct empirical evidence of a strong association between brain 
2014; Liu et al., 2014). Notably, Qing and Gong (2016) provide 
suggesting that the two brain measures are related (Li et al., 
matter (GM), suggesting that ALFF derives from neural activity 
spontaneous fluctuation in a particular voxel within the BOLD 
techniques, such as amplitude of low-frequency fluctuations 
deficits spanning the multiple brain regions such as frontal, 
temporal, and parietal lobes (Honea et al., 2005; Cronenwett and 
Csernansky, 2010; Yang et al., 2021), accompanied by functional 
abnormalities (Lawrie et al., 2002; Zhou et al., 2007). Despite 
the availability of various magnetic resonance imaging (MRI) 
techniques, the consistency of findings across studies remains a 
significant challenge. Previous studies have demonstrated gray 
matter volume (GMV) decreased in SZ by 2% (Wright et al., 2000; 
Vita et al., 2012). However, Benedicto reported no differences 
in GMV between SZ and healthy volunteers (Kim et al., 2000). 
Besides, two studies have suggested abnormally increased GMV 
in the orbitofrontal cortex (Hopptman et al., 2005; Lacerda et al., 
2007), whereas a third study detected the opposite change in 
the same region (Nakamura et al., 2008). Furthermore, a recent 
selective meta-analysis concluded that the variability of GMV 
in specific areas such as the putamen and temporal lobe was 
significantly greater in patients (Brugger and Howes, 2017). 
Scholars have emphasized more extensive brain network 
dysfunction. However, the specific pathological mechanism is not 
clear, and the high heterogeneity between the studies has also led 
to more controversy and discussion. For SZ with antipsychotics, 
there are few studies of structural imaging combined with 
functional imaging. One of the commonly used functional MRI 
techniques, such as amplitude of low-frequency fluctuations 
(ALFF), has been developed, which measures the intensity of 
spontaneous fluctuation in a particular voxel within the BOLD 
signal (Zang et al., 2007). The intrinsic brain activity consumes 
over 95% of the brain’s energy and is likely to play a critical 
role in brain function (Zhang and Raichle, 2010). A number of 
recent studies have revealed synchronous changes in brain 
volume and ALFF values in specific disease processes, suggesting 
that the two brain measures are related. It is most reliable in gray 
matter (GM), suggesting that ALFF derives from neural activity 
(Vesa et al., 2003). Studies have revealed synchronous changes 
in brain volume and ALFF values in specific disease processes, 
suggesting that the two brain measures are related (Li et al., 
2014; Liu et al., 2014). Notably, Qing and Gong (2016) provide 
direct empirical evidence of a strong association between brain 
size/volume and intrinsic brain activity, suggesting that brain size 
serves as a structural substrate for the intrinsic brain activity of 
the human brain.

Conclusion: GMV loss appeared to be pronounced to longer-term antipsychotics, whereby imbalanced alterations in regional low-frequency fluctuations persisted unaffected by antipsychotic treatment. Our findings may help to understand the disease course of SZ and potentially identify a reliable neuroimaging feature for diagnosis.

Keywords: schizophrenia, gray matter volumes, amplitude of low frequency fluctuations, antipsychotics, real-world observation

INTRODUCTION

Psychotropic medications have long confounded findings from 
neuroimaging studies. Their effects result in inconsistent findings 
and hamper efforts to understand further the pathophysiology of 
neuropsychiatric disorders such as schizophrenia (SZ). Mounting 
neuroimaging studies have indicated SZ that features structural 
deficits spanning the multiple brain regions such as frontal, 
temporal, and parietal lobes (Honea et al., 2005; Cronenwett and 
Csernansky, 2010; Yang et al., 2021), accompanied by functional 
abnormalities (Lawrie et al., 2002; Zhou et al., 2007). Despite 
the availability of various magnetic resonance imaging (MRI) 
techniques, the consistency of findings across studies remains a 
significant challenge. Previous studies have demonstrated gray 
matter volume (GMV) decreased in SZ by 2% (Wright et al., 2000; 
Vita et al., 2012). However, Benedicto reported no differences 
in GMV between SZ and healthy volunteers (Kim et al., 2000). 
Besides, two studies have suggested abnormally increased GMV 
in the orbitofrontal cortex (Hopptman et al., 2005; Lacerda et al., 
2007), whereas a third study detected the opposite change in 
the same region (Nakamura et al., 2008). Furthermore, a recent 
selective meta-analysis concluded that the variability of GMV 
in specific areas such as the putamen and temporal lobe was 
significantly greater in patients (Brugger and Howes, 2017). 
Scholars have emphasized more extensive brain network 
dysfunction. However, the specific pathological mechanism is not 
clear, and the high heterogeneity between the studies has also led 
to more controversy and discussion. For SZ with antipsychotics, 
there are few studies of structural imaging combined with 
functional imaging. One of the commonly used functional MRI 
techniques, such as amplitude of low-frequency fluctuations 
(ALFF), has been developed, which measures the intensity of 
spontaneous fluctuation in a particular voxel within the BOLD 
signal (Zang et al., 2007). The intrinsic brain activity consumes 
over 95% of the brain’s energy and is likely to play a critical 
role in brain function (Zhang and Raichle, 2010). A number of 
recent studies have revealed synchronous changes in brain 
volume and ALFF values in specific disease processes, suggesting 
that the two brain measures are related. It is most reliable in gray 
matter (GM), suggesting that ALFF derives from neural activity 
(Vesa et al., 2003). Studies have revealed synchronous changes 
in brain volume and ALFF values in specific disease processes, 
suggesting that the two brain measures are related (Li et al., 
2014; Liu et al., 2014). Notably, Qing and Gong (2016) provide 
direct empirical evidence of a strong association between brain 
size/volume and intrinsic brain activity, suggesting that brain size 
serves as a structural substrate for the intrinsic brain activity of 
the human brain.

However, studies of ALFF in SZ also have given inconsistent 
results. A recent meta-analysis in SZ indicated the decreased 
ALFF primarily in the somatosensory cortex, posterior parietal 
cortex, and occipital cortex and increased ALFF mainly in the 
bilateral medial temporal cortex and medial prefrontal cortex 
(Xu et al., 2015). However, some studies have contrarily reported 
decreased ALFF in medial prefrontal areas (Huang et al., 2010; 
Wenting et al., 2013). Similarly, two studies have suggested 
abnormally high intrinsic activity in the bilateral putamen 
(Huang et al., 2010; He et al., 2013); Lui did not report such 
high activity though (Lui et al., 2010). Altogether, although 
multiple factors could contribute to inconsistent findings, such 
as differences in sample characteristics or exact methodology, the 
inconsistencies across studies may, in part, reflect the effects of 
antipsychotics in SZ.

What the role antipsychotic treatment played on the 
pathophysiologic process of brain deficits in SZ remains unclear. 
Antipsychotics have been associated with GMV deficits in the 
frontotemporal cortex and the whole brain in SZ (Leung et al., 
2011; Ahmed et al., 2015) but have also been associated with 
no change or increase in GMV (Halim et al., 2004; Ho et al., 
2011). Also, a meta-analysis indicated that more significant 
volumetric variation in the brain structure of individuals with 
SZ compared with controls could suggest that antipsychotic 
levels may somehow be associated with greater heterogeneity 
in brain volume in SZ (Kuo and Pogue-Geile, 2019). However, 
there are still relatively limited studies regarding the influence 
of medications in ALFF. Six-week antipsychotic treatment has 
been associated with increases of ALFF in the frontal gyrus, 
parietal lobule, temporal gyrus, and right caudate (Lui et al., 
2010). Furthermore, after 1-year treatment of antipsychotics, the 
majority of ALFF values did not significantly change between 
baseline and follow-up imaging except right inferior parietal 
lobule and orbitofrontal cortex and right occipital gyrus (Li 
et al., 2016). The earlier findings suggest that neuroimaging 
measures vary in their susceptibility to medication effects and 
that some measures more robustly reflect disease processes versus 
treatment response.

Furthermore, although experts agree on the efficacy of 
antipsychotics in alleviating psychotic symptoms during the 
early most acute phase (0–2 months), the longer-term effects 
of antipsychotics on the brain have long been controversial 
(Vita et al., 2015; van Erp et al., 2018; Liu et al., 2020). 
Given that evidence for the benefits of antipsychotics extends 
only to approximately 0–2 years, what to do in the longer 
term draws our attention. One recent naturalistic longitudinal 
study of patients with psychosis with a 3-year follow-up period 
reported a significantly increased rate of cortical loss compared
with healthy controls (HCs; Akudjedu et al., 2020). However, infrequent studies assessed how the brain of patients with SZ changes when treated for midterm to long term with antipsychotic medications. Moreover, views about the longer-term (>2 months) efficacy of antipsychotics often based on the results from longitudinal evaluations are subject to the risk of bias caused by dropout or statistical effectiveness reduction. For this reason, the cross-sectional studies combining structural and functional imaging based on the natural world can bring complementary information for brain changes at this stage.

Therefore, in this study, we examined GMV and ALFF using voxel-based morphometry and resting-state functional magnetic resonance imaging (fMRI) techniques in SZ based on medication status: unmedicated (medication naive or not taking medications for at least 4 weeks before scan) and medicated (taking medications for at least 8 weeks before the scan, more than half of them for 2–4 years). We aimed for a preliminary real-world observation with no study-related and longer-term treatment changes to capture the typical conditions of neuroimaging studies to provide some basis for the identification of objective image indicators in patients with SZ. Thresholds for medication status were determined based on prior findings of antipsychotic effects on the brain as early as 1 month after treatment initiation in SZ and standards for unmedicated status by other studies in the literature (Mcclure et al., 2008; Leung et al., 2011; Kraguljac et al., 2016). We also examined associations between structural and functional metrics and clinical markers in patients with SZ.

### MATERIALS AND METHODS

#### Subjects

The Institutional Review Board of China Medical University approved this study, and all participants provided written informed consent after a detailed description of the study. Participants in this study included 89 individuals with SZ who had been taking only atypical antipsychotics for more than 8 weeks before the time of scan (med-SZ) and 81 individuals with

| TABLE 1 | Demographic and clinical characteristics of healthy controls, medicated schizophrenia, and unmedicated schizophrenia. |
|---------|----------------------------------------------------------------------------------------------------------------------------------|
|         | HC (n = 235)                                                                                                                   | Med-SZ (n = 89) | Unmed-SZ (n = 81) | F/χ²/t-values | P-values |
| Demographic characteristic |                                                                                                                                |               |               |               |          |
| Age at scan, years          | 28.17 (0.53)                                                                  | 27.65 (10.06) | 25.53 (9.30) | 2.740a       | 0.066    |
| Age distribution            |                                                                                                                                |               |               |               |          |
| –15 to 28                    | 161 (68.51%)                                                                                                                | 53 (59.55%)   | 53 (65.43%) |              |          |
| –29 to 42                    | 54 (22.98%)                                                                   | 24 (26.97%)   | 22 (27.16%) |              |          |
| –43 to 55                    | 20 (8.51%)                                                                  | 12 (13.48%)   | 6 (7.40%)     |              |          |
| Sex (male:female)           | 93 (39.57%)                                                                  | 44 (49.44%)   | 32 (43.20%) | 2.789a       | 0.248    |
| Right handedness            | 217 (92.34%)                                                                                                                | 78 (87.64%)   | 68 (83.95%) | 2.525a       | 0.640    |
| Education                   | 15.08 (3.06)                                                                  | 12.06 (2.98)  | 10.93 (3.00) | 70.832       | <0.001   |
| Clinical characteristic     |                                                                                                                                |               |               |               |          |
| First episode, yes          | 44 (49.44%)                                                                  | 71 (87.65%)   | \             | <0.001       |
| Illness duration (months)   | 43.07 (51.01)                                                                                                               | 8.84 (17.83)  | 31.14p        | <0.001      |
| Medication use\(^c\)        | \                                                                               |               |               |               |          |
| Durations (months)          | 12.34 (13.74)                                                                                                               | \             | \             | \           |
| -Olanzapine                 | 21                                                                             |               |               |               |          |
| -Clozapine                  | 13                                                                             |               |               |               |          |
| -Risperidone                | 41                                                                             |               |               |               |          |
| -Aripiprazole               | 19                                                                             |               |               |               |          |
| -Ziprasidone                | 4                                                                              |               |               |               |          |
| -Quetiapine                 | 5                                                                              |               |               |               |          |
| Olanzapine equivalents      | 3.93 (6.15)                                                                   | n = 159       | n = 83        |               |          |
| BPRS-Factors                | 4.28 (0.83)                                                                   | 6.89 (3.72)   | 8.90 (4.35)   | 5.342p       | 0.009    |
| Anxiety and depression      |                                                                                                                                |               |               |               |          |
| Lack of energy              | 4.03 (0.21)                                                                   | 6.53 (3.00)   | 8.14 (4.54)   | 11.35p       | <0.001   |
| Thought disorder            | 4 (0)                                                                         | 6.65 (3.77)   | 9.39 (4.89)   | 8.644p       | 0.178    |
| Activity                    | 3.06 (0.26)                                                                   | 4.29 (2.09)   | 4.78 (2.47)   | 3.267p       | <0.001   |
| Hostility                   | 3.02 (0.14)                                                                   | 4.61 (2.78)   | 7.44 (4.01)   | 18.19p       | <0.001   |
| BPRS-Total score            | 18.39 (1.21)                                                                  | 28.98 (10.30) | 39.03 (14.62) | 9.042p       | 0.002    |

HC, healthy controls; med-SZ, medicated schizophrenia; unmed-SZ, unmedicated schizophrenia; BPRS, Brief Psychiatric Rating Scale. Data are n (%) or mean (SD).

\(^a\)Examination among healthy control, medicated schizophrenia, and unmedicated schizophrenia groups.

\(^b\)Examination between medicated schizophrenia and unmedicated schizophrenia groups.

\(^c\)This refers to medication patients were prescribed on day of their MRI scan and not to their cumulative lifetime exposure.
SZ (unmed-SZ) who were either antipsychotics naïve \( (n = 31, 38.27\%) \) or not taking antipsychotics for at least 4 weeks at the time of scan \( (n = 50, 61.73\%) \) and 235 HCs aged 15–55 years. We reviewed information on the type and dosage of medication recorded at the time of the MRI scan. Med-SZ was treated with antipsychotics including clozapine, risperidone, olanzapine, aripiprazole and quetiapine, aripiprazole, and ziprasidone. The doses of antipsychotics were converted to olanzapine equivalents based on defined daily doses (Leucht et al., 2016). All participants were recruited from the outpatient clinics of the Department of Psychiatry, The First Affiliated Hospital of China Medical University, Shenyang, China, and HC participants were recruited from Shenyang, China, by advertisement. The absence or presence of Axis I disorders was independently assessed by two trained psychiatrists using the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Axis I Disorders for participants older than 18 years and the Schedule for Affective Disorders and Schizophrenia for School-Age Children—Present and Lifetime Version (K-SADS-PL) for participants younger than 18 years. SZ participants met the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, diagnostic criteria for SZ, schizophreniform disorder, schizoaffective disorder, and no other Axis I disorder. HC participants did not have current or lifetime Axis I disorder or history of psychotic, mood, or other Axis I disorders in first-degree relatives (as determined from detailed family history). For all participant groups, individuals were excluded for the history of substance or alcohol abuse or dependence, head injury, neurologic or concomitant major medical disorder, and any MRI contraindications for MRI symptom measures using the Brief Psychiatric Rating Scale (BPRS) in patients with SZ. Table 1 outlines the participants' demographic and clinical status at the time of testing.

### Image Acquisition

The scan was performed using a 3T MRI scanner (General Electric, Milwaukee, WI, United States) at the Image Institute of The First Affiliated Hospital of China Medical University, Shenyang, China. The three-dimensional fast spoiled gradient-echo sequence was used to obtain sagittal T1-weighted structural images of the whole brain. Scanning parameters were as follows: repetition time = 7.1 ms, echo time = 3.2 ms, field of view = 24 cm × 24 cm, voxel size = 1 mm × 1 mm × 1 mm, slice thickness = 1.0 mm without a gap, 176 slices in total, and the scan time = 8 min 6 s. Functional images were collected using a gradient echo-planar imaging sequence: repetition time = 2,000 ms, echo time = 30 ms, field of view = 240 cm × 240 cm, flip angle = 90°, matrix = 64 × 64, and slices = 35. Participants were instructed to rest with their eyes closed but remain awake during scanning.

### Structural Magnetic Resonance Imaging Data Processing

Processing was performed using the DARTEL algorithm Statistical Parametric Mapping software (SPM8)\(^1\) under the MATLAB R2010b platform (MathWorks, Sherborn, MA, United States). Briefly, the segmentation function was used to divide the regions into GM, white matter, and cerebrospinal fluid using the “new segment” tool implemented in SPM8. During spatial normalization, inter-subject registration was achieved using separate registration based on group assignment. A modulation step was used to ensure that the overall amount of tissue in a class was unaltered. The segmented images were normalized to the Montreal Neurological Institute template and were smoothed with an 8-mm full width at a half-maximum Gaussian filter. The voxel size of data acquisition was 1 mm\(^3\), and the voxel size of normalized data was 1.5 mm\(^3\).

### Functional Magnetic Resonance Image Processing and Amplitude of Low-Frequency Fluctuation Calculation

Resting-state fMRI data preprocessing was carried out using Statistical Parametric Mapping 8 (SPM)\(^2\). Data Processing Assistant for Resting-State fMRI (DPARSF, V2.0_101025)\(^3\) was based on SPM8. For each participant, the first 10 volumes of scanned data were discarded to allow for steady-state magnetization. Further data preprocessing included slice timing correction and head motion correction. Each participant's motion was assessed by means of translation/rotation and an exclusion criterion (translation > 3 mm, rotation > 3° in each participant). Then, spatial normalization was performed using the standard echo-planar imaging template from the Montreal Neurological Institute Spatial smoothing, which was done with a 6-mm full width at a half-maximum Gaussian filter, and linear detrending was performed to remove linear trends (Cordes et al., 2001). The filtered time series was transformed into the frequency domain with a fast Fourier transform, and the power spectrum was then obtained. ALFF was measured by obtaining the square root of the signal across 0.01–0.08 Hz for each voxel.

### Statistical Analysis

Analyses of demographic and clinical characteristics were performed using analysis of variance and chi-square tests. Results were considered significant at \( p < 0.05 \). To compare GMV with ALFF values among the med-SZ, unmed-SZ, and HC groups, whole brain GMV and ALFF values comparisons among three groups were performed using a full-factorial design, with age and sex as covariates, using SPM8 (Wellcome Trust Centre for Neuroimaging, see text footnote 1). The GMV and ALFF value differences were considered significant at a height threshold of \( p < 0.05 \), family-wise error (FWE) corrected for multiple comparisons, and an extended threshold of 20 voxels (Liao et al., 2015). GMV and ALFF values were extracted from all significant regions in the three-group analysis and analyzed in post hoc pair-wise t-contrasts (med-SZ vs. unmed-SZ, med-SZ vs. HC, and unmed-SZ vs. HC) using SPSS. Duration of illness was included as a covariate of non-interest in the patient subgroup comparison. To determine age-related effects on GMV and ALFF

---

\(^1\)http://www.fil.ion.ucl.ac.uk/spm/software/spm8/
\(^2\)http://www.fil.ion.ucl.ac.uk/spm
\(^3\)http://www.restfmri.net
values in the two patient groups (medicated and unmedicated), we used the mean values of GMV and ALFF in regions showing the group-level difference and ran a general linear model in SPSS. The GMV and ALFF values were considered as dependent variables. Fixed factors included age and group (med-SZ and unmed-SZ). Analyses were also performed with false discovery rate (FDR) corrected for multiple comparisons to further confirm the findings of age-related effects.

We used exploratory Pearson’s correlation analyses to examine the relationship between GMV/ALFF values and BPRS scores and medication time in each patient group. Analyses were also performed with FDR corrected for multiple comparisons to further confirm the findings of correlation after FDR correction; \( p < 0.005 \) was considered significant in correlation analysis.

**RESULTS**

**Demographic and Clinical Data**

There was no significant difference among med-SZ, unmed-SZ, and HC groups in age \( (p = 0.066) \) or sex \( (p = 0.248) \), and handedness \( (p = 0.640) \). The unmed-SZ group had significantly
shorter illness duration, lower first-episode rate, and higher BPRS scores compared with the med-SZ group (see Table 1 for details).

**Gray Matter Volume Findings**
Significant group differences were found in several regions consisting of the prefrontal cortex, temporal lobe, cingulate gyr, and insula (df = 2, p < 0.05, FWE corrected) (Figure 1 and Table 2). Compared with unmed-SZ and HC groups, the med-SZ demonstrated decreased GMVs located in bilateral middle frontal gyrus, bilateral superior medial frontal gyrus, bilateral superior temporal gyrus, bilateral anterior cingulate gyr, bilateral middle cingulate gyr, right Rolandic operculum, right superior frontal gyrus, middle orbital frontal gyrus, left fusiform gyrus, and left insula. All clusters except the left superior temporal cortex survived when illness duration was included as a covariate in comparison between med-SZ and unmed-SZ. Significant decreases were found in the left fusiform gyrus and left superior temporal gyrus in unmed-SZ compared with HC (Figure 1 and Table 2).

**Amplitude of Low-Frequency Fluctuation Findings**
The three-group analysis of ALFF found four clusters showing significant group differences (df = 2, p < 0.05, FWE corrected). These clusters are situated in the bilateral occipital lobe, bilateral striatum, and left parahippocampal gyrus (Supplementary Figure 1 and Table 3). Compared with HC, med-SZ and unmed-SZ had significant decreases of ALFF values in bilateral lingual and calcarine gyrus and significant increases mainly in bilateral caudate and putamen, as well as left parahippocampal gyrus. No differences were observed between med-SZ and unmed-SZ (Figure 2 and Table 3).

**Age-Related Differences in Gray Matter Volume and Amplitude of Low-Frequency Fluctuation**
We examined relationships between age and GMV that differed between the two groups. More specifically, age-related GMV effects were seen in all regions, which showed group-level differences except fusiform gyrus. Post hoc analyses showed that the age-related decline in GMV of the bilateral middle frontal gyrus, left inferior pars triangularis, and right middle cingulum in medicated patients was significantly greater than that in unmedicated patients. Unmedicated patients showed significantly faster age-related GMV decline in the right rectus gyrus, left insula, bilateral superior temporal gyrus, and right anterior cingulum than medicated subjects. We also examined relationships between age and ALFF values that differed between the two groups but found no association after FDR correction.

**Correlations With Clinical Variables and Medication Time**
For both med-SZ and unmed-SZ, BPRS scores were positively correlated with GMV in bilateral middle frontal gyrus, bilateral superior medial frontal gyrus, right superior temporal gyrus, bilateral anterior cingulate gyr, bilateral middle cingulate gyr, right Rolandic operculum, right superior frontal gyrus, middle orbital frontal gyrus, and left insula. After FDR correction, most correlations survived, except the correlation between BPRS scores and the GMV in left fusiform and left superior temporal gyrus (p < 0.05, FDR corrected) (Supplementary Table 1 and Table 2). No significant correlation was found between ALFF values and BPRS scores (Supplementary Table 2 and Table 3). Besides, we did not detect any relation between medication time and GMV/ALFF values (Supplementary Tables 1, 2, and 3).

**DISCUSSION**
In the current study, we compared the susceptibility of different imaging measures with antipsychotics. We found significant GMV decreases in the prefrontal cortex, temporal lobe, cingulate gyr, and left insula in med-SZ compared with unmed-SZ and HC. Among these regions, unmed-SZ demonstrated lower GMV in the left superior temporal cortex and left fusiform than HC additionally. We also found a significant correlation between GMV loss and decline of BPRS scores. No significant differences in ALFF were found based on medication status, and no significant correlations between ALFF and BPRS scores were observed. Both med- and unmed-SZ had significantly increased ALFF in the anterior cerebrum, including bilateral striatum and left parahippocampal, and decreased ALFF in posterior visual cortices, including the calcarine and lingual gyrus, compared with HC. Our findings indicate that GMV may be susceptible to medication effects, whereas ALFF is not in SZ.
It is widely accepted that SZ is characterized by extensive GMV abnormalities (Kubicki et al., 2002; Koolschijn et al., 2010; Pinacamacho et al., 2016); however, the contribution of medication effects to these alterations are unclear. Moreover, further investigation is needed to clarify if specific regions are more affected by neuroleptics. Our findings suggest that antipsychotic treatment may be more influential in GMV in the frontal, temporal, cingulate, and insula regions. This result is in line with evidence from substantial imaging studies indicating that antipsychotic treatment can result in GMV loss in SZ (Mccormick et al., 2005; Ho et al., 2011). Tyler et al. reported that significant cortical thinning was identified in the medicated patient group relative to the control group in prefrontal, temporal, parietal, and occipital cortices (Lesh et al., 2015). The unmedicated patient group showed no significant cortical thickness differences from the control group. Furthermore, meta-regression analyses also reported that GMV in medial frontal, anterior cingulate cortices, and left insular regions were more decreased in med-SZ (Radua et al., 2012). A study of 211 individuals with SZ over a mean 7.2-year period found that antipsychotics significantly influenced brain volumes even after accounting for illness duration, illness severity, and substance use (Ho et al., 2011). Antipsychotic dosing explained 1.7% of the decreases in total GMV (Ho et al., 2011). Animal studies also support the earlier findings that non-human primates given doses of antipsychotics similar to those given to humans showed brain...
volume reductions of around 10%, mostly attributable to loss of the glial cells that support and protect neurons (Cyranoski, 2011). Although substantial findings, including our results, suggest GMV loss is induced by antipsychotics (Lieberman et al., 2005; Radua et al., 2012), a few findings have identified conserved or even increased GMV in SZ with specific atypical antipsychotics (Gur et al., 1998; Molina et al., 2005), and that may be attributed to differences in sample size, the definition of medicated and unmedicated groups: in many of these studies, the sample sizes were modest (<30 subjects); the treatment duration is relatively short (mostly <6 weeks).

Gray matter volume changes in SZ do not appear entirely due to medication effects. We found significant GMV loss in the left superior temporal cortex and left fusiform in unmed-SZ, compared with HC. Previous studies have shown GMV reduction in left posterior superior temporal gyrus and left fusiform in first-episode SZ (Hirayasu et al., 1998; Lee et al., 2002, 2015). Our findings replicate prior findings of decreased left fusiform volume in treatment-naïve SZ (Guo et al., 2013). Structural alterations in the left superior temporal cortex and left fusiform structural abnormalities appear less affected by illness chronicity and medication effects and hence may serve as potential biomarkers for SZ.

Gray matter volumes in prefrontal, temporal, cingulate, and insula were positively correlated with BPRS scores, consistent with previous findings (Wenting et al., 2013; Liao et al., 2015). We found GMV deficits found in frontotemporal regions that have been implicated in aggression, emotional withdrawal, blunted affect, and conceptual disorganization in SZ (Lieberman et al., 2005; Cobia et al., 2012; Fusarpoli et al., 2013). The correlation between GMV deficits and BPRS scores may reflect GMV as a marker of disease state (versus trait) and treatment response.

We found age-related differences in GMV between med- and unmed-SZ. More specifically, in patients with med-SZ, imaging studies found accelerated age-related GMV decline than unmed-SZ in all regions showing group-level differences except the fusiform gyrus. To our best knowledge, this is the first cross-sectional study that explores the relation between GMV and age with or without longer medication use. This finding is also consistent with previous studies suggesting that progressive brain GMV changes during the life-long course of SZ appeared in part to be related to antipsychotics (Ho et al., 2011; Lesh et al., 2015). Moreover, a recent randomized, double-blind placebo-controlled clinical trial design study found a significant treatment-group \( \times \) time interaction in relation to cortical thickness with 36-week treatment (Voineskos et al., 2020). Given that medication use may bring out a detrimental effect of progressive GMV changes, which are typically interpreted in psychiatric and neurologic disorders as non-desirable, our findings could support a reconsideration of the risks and benefits of antipsychotics.

Here, we provided evidence focused on the longer-term antipsychotic treatment showing that we may underestimate the risks of longer-term antipsychotic treatment. The temporal relief of symptoms may be a compensation for GMV loss; the coverage of the worrying issue of the longer-term effects of antipsychotics on brain structure loss must not be overlooked. Recently, Correll et al. (2018) argued for a positive view of the risk–benefit ratio for long-term continuous antipsychotic treatment of SZ. However, Correll et al. (2018) too readily dismiss the evidence that prolonged antipsychotic use is associated with decreased GM and fail to cite the monkey and rodent studies in which administration of antipsychotics causes brain volume losses (Cyranoski, 2011). As we have noted, the association between cumulative dose of antipsychotics and general GMV reduction has been repeatedly reported. Moreover, the accompanying dopamine hypersensitivity psychosis and poor long-term (7–20 years) prognosis suggest the inevitable issue of its adverse effects on brain structure (Martin and Jobe, 2018). Furthermore, some studies assess whether patients with SZ improve when treated longer than 2 or 3 years with antipsychotic medications (Morgan et al., 2014; Harrow et al., 2017; Velthorst et al., 2017). Interestingly, unlike short-term studies, none of them showed positive long-term results. Although administered widely, we still do not have a clear knowledge of all of the antipsychotic effects. Further questions and studies of it would seem critical.

Our findings with ALFF suggest that ALFF is less influenced by medication and disease state. We found increased ALFF in the anterior cerebrum, including the bilateral striatum, and decreased ALFF in the posterior visual cortex, consistent with previous studies in both unmed- and med-SZ (He et al., 2013; Li et al., 2017; Chang et al., 2019). A meta-analysis also concluded that the foci with increased ALFF are mainly located in the striatum and decreased ALFF situated in the occipital cortex consistently (Xu et al., 2015). The striatum, together with other basal ganglia nuclei, regulates information flow to and from the cerebral cortex and other related subcortical regions (such as the thalamus). Our finding of altered ALFF in the bilateral striatum is consistent with prior studies implicating striatal abnormalities in the pathophysiology of SZ. Prior functional and metabolic studies have found increased striatal dopamine neurotransmission and activity in SZ (Kegeles et al., 2010; Zhuo et al., 2014), and our results may support the hypothesis that the striatum of SZ is in a state of hyper-dopamine (Abidargham, 2014). Bilateral lingual and calcarine gyrus, which function as the primary visual cortex, have been related to visual hallucinations in most studies (González-Hernández et al., 2003;
Onitsuka et al., 2007; Hoptman et al., 2010; Lang et al., 2010), suggesting that the visual cortex alterations may be important in SZ. We found that med-SZ and unmed-SZ showed decreased ALFF values in the posterior visual cortex, including lingual gyrus and calcarine gyrus, consistent with the hypothesis that SZ is associated with low-level sensory functions (Butler et al., 2001; Butler and Javitt, 2005). For instance, the magnocellular deficits were found in SZ, which may lead to their higher-level visual processing difficulties as well (Butler and Javitt, 2005). However, a previous functional neuroimaging study reported a different result from ours. Increased ALFF was found in the bilateral prefrontal and parietal cortex, left superior temporal cortex, and right caudate nucleus after 6-week treatment of atypical antipsychotics (Lui et al., 2010), but this finding has not been replicated, and the heterogeneity of findings may be caused by sample differences such as illness chronicity. The ALFF signal is correlated with baseline cerebral blood flow and is thought to reflect spontaneous, intrinsic neuronal activity (Zhou et al., 2010). ALFF signal is mostly reliable in GM, not white matter, suggesting that ALFF derives from neural activity, although further work is needed for the exact neural substrate for ALFF (Kiviniemi et al., 2003). Our studies suggest that these abnormalities may be trait-like alterations of brain function that current antipsychotics do not effectively normalize.

No significant correlation was found between ALFF and BPRS, indicating that amplitude cannot be used as a quantitative marker for the assessment of symptoms of SZ, although it can be used in a qualitative way to help locate aberrant functional areas. Previous studies have shown that striatal ALFF was not associated with psychotic symptom severity in the first episode and medication naïve SZ (Huang et al., 2010; He et al., 2013; Wenting et al., 2013; Li et al., 2017). Anna et al. reported that SZ exhibited decreased ALFF values in the occipital pole and lingual gyrus regardless of the severity of auditory verbal hallucinations (Alonso-Solís et al., 2017). Thus, ALFF appears to be a relatively static measure that does not vary with state changes in SZ.

There are several limitations to this study. As this represented a real-world observational study, data regarding medication dose, compliance, and duration were not available or included in our analyses. Besides, the ratio of antipsychotic-naïve in the unmed-SZ was 38.3%, which may be a potential confounding effect of medication exposure in the unmed-SZ group. Furthermore, the study was cross-sectional and not longitudinal, in which the same individual was observed in medicated and unmedicated state, although the demographic data among the three groups have been matched to reduce the influence of confounding factors to a certain extent. Thus, further research is needed to confirm the generalizability of our findings.

Through real-world observation, our study suggests that GMV is a sensitive spatiotemporal marker of longer-term pharmacologic intervention in the brain, whereas ALFF is a relatively static measure reflecting more core disease traits that are less influenced by medication status and disease state (e.g., active versus remitted). Our study underscores the need for careful selection of neuroimaging measures based on study purpose and the focus on longer-term antipsychotics (e.g., use GMV when primary interest in treatment response and ALFF when main focus on disease trait).

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by the Medical Science Research Ethics Committee of The First Affiliated Hospital of China Medical University. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

AUTHOR CONTRIBUTIONS
FW and YT designed the experiments. YC, MC, RF, JD, ZY, YW, SW, and XJ acquired the data. YC, RF, and XZ analyzed the data. YC and FW wrote the manuscript. FYW and FW reviewed or edited the manuscript. All authors discussed the results, reviewed the manuscript, and meet the criteria for authorship to be named as authors.

FUNDING
This study was supported by the National Key R&D Program of China (grant nos. 2018YFC1311600 and 2016YFC1306900 to YT), Liaoning Revitalization Talents Program (grant #LYC1808036 to YT), Science and Technology Plan Program of Liaoning Province (2015225018 to YT), National Science Fund for Distinguished Young Scholars (81725005 to FW), Liaoning Education Foundation (Pandeng Scholar to FW), Innovation Team Support Plan of Higher Education of Liaoning Province (LT2017007 to FW), and Major Special Construction Plan of China Medical University (3110117059 and 3110118055 to YT), National Science Fund of China (grant nos. 2018YFC1311600 and 2016YFC1306900 to YT), and National Natural Science Foundation of China (62176120 to XJ).

ACKNOWLEDGMENTS
We thank all the participants for their cooperation, and we are grateful for the support of Shenyang Mental Health Center, Department of Psychiatry and Radiology, The First Affiliated Hospital of China Medical University.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnins.2021.749316/full#supplementary-material
REFERENCES

Abidargham, A. (2014). Schizophrenia: overview and dopamine dysfunction. J. Clin. Psychiatry 75:e31. doi: 10.1089/jcp.2013.1028

Ahmed, M., Cannon, D. M., Scanlon, C., Holleran, L., Schmidt, H., Mcfarland, J., et al. (2015). Progressive brain atrophy and cortical thinning in schizophrenia after commencement of clozapine treatment. Neuropsychopharmacology 40, 2409–2417. doi: 10.1038/npp.2015.90

Akudjedu, T., Tronchin, G., Mcinerney, S., Scanlon, C., Kenney, J., Mcfarland, J., et al. (2020). Progression of neuroanatomical abnormalities after first-episode of psychosis: a 3-year longitudinal sMRI study. J. Psychiatr. Res. 130, 137–151. doi: 10.1016/j.jpsychires.2020.07.034

Alonso-Solís, A., Vives-Gilabert, Y., Portella, M. J., Rabella, M., Grasa, E. M., Boldan, A., et al. (2017). Altered amplitude of low frequency fluctuations in schizophrenia patients with persistent auditory verbal hallucinations. Schizophr. Res. 189, 97–103. doi: 10.1016/j.schres.2017.01.042

Brugger, S. P., and Howes, O. D. (2017). Heterogeneity and homogeneity of regional brain structure in schizophrenia: a meta-analysis. JAMA Psychiatry 74, 1104–1111. doi: 10.1001/jamapsychiatry.2017.2663

Butler, P. D., and Javitt, D. C. (2005). Early-stage visual processing deficits in schizophrenia. Curr. Opin. Psychiatry 18, 151–157. doi: 10.1097/00050300-200503000-00008

Butler, P. D., Schechtler, I., Zemon, V., Schwartz, S. G., Greenstein, V. C., Gordon, J., et al. (2001). Dysfunction of early-stage visual processing in schizophrenia. Am. J. Psychiatry 158, 1126–1133.

Chang, M., Edmiston, E. K., Womer, F. Y., Zhou, Q., Wei, S., Jiang, X., et al. (2019). Spontaneous low-frequency fluctuations in the neural system for emotional perception in major psychiatric disorders: amplitude similarities and differences across frequency bands. J. Psychiatry Neurosci. 44, 132–141. doi: 10.1503/jpn.170226

Cobia, D. J., Smith, M. J., Wang, L., and Csernansky, J. G. (2012). Longitudinal progression of frontal and temporal lobe changes in schizophrenia. Schizophr. Res. 139, 1–6. doi: 10.1016/j.schres.2012.05.002

Cordes, D., Haughton, V. M., Arfanakis, K., Carew, J. D., Turski, P. A., Moritz, C. H., et al. (2001). Frequencies contributing to functional connectivity in the cerebral cortex in “resting-state” data. Arch. Gen. Psychiatry 58, 2226–2233.

Correll, C. U., Rubio, J. M., and Kane, J. M. (2018). What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry 17, 149–160. doi: 10.1002/pps.20516

Cronenwett, W. J., and Csernansky, J. (2010). Thalamic pathology in schizophrenia. Curr. Top. Behav. Neurosci. 4, 509–528. doi: 10.1007/877845_2010_35

Cyranoski, D. (2011). Antipsychotic drugs could shrink patients’ brains. Nature. doi: 10.1038/news.2011.75

van Erp, T. G. M., Walton, E., Hibar, D. P., Schmaal, L., Jiang, W., et al. (2015). Progressive brain atrophy and cortical thinning in schizophrenia and effects of antipsychotic medications on neurogenesis in the adult rat hippocampus. Neuropsychopharmacology 29, 1063–1069. doi: 10.1038/npp.2015.042

Harrington, N. D., Weickert, C. S., McLintock, B. W., Weinberger, D. R., and Lipska, B. K. (2004). Effects of chronic haloperidol and clozapine treatment on neurogenesis in the adult rat hippocampus. Neuropsychopharmacology 29, 1104–1111. doi: 10.1016/j.neuropharm.2007.06.009

He, Z., Deng, W., Li, M., Chen, Z., Jiang, L., Wang, Q., et al. (2013). Aberrant intrinsic brain activity and cognitive deficit in first-episode treatment-naive patients with schizophrenia. Psychol. Med. 43, 769–780. doi: 10.1017/S0033291712001638

Hiyazasu, Y., Shenton, M. E., Salisbury, D. F., Dickey, C. C., Fischer, I. A., Mazzoni, P., et al. (1998). Lower left temporal lobe MRI volumes in patients with first-episode schizophrenia compared with psychotic patients with first-episode affective disorder and normal subjects. Am. J. Psychiatry 155, 1384–1391. doi: 10.1176/ajp.155.10.1384

Ho, B. C., Andreasen, N. C., Ziebell, S., Pierson, R., and Magnotta, V. (2011). Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch. Gen. Psychiatry 68, 128–137. doi: 10.1010/ajp.2010.199

Honea, R., Crow, T. J., Passingham, D., and Mackay, C. E. (2005). Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. Am. J. Psychiatry 162, 2233–2245. doi: 10.1176/appi.ajp.162.12.2333

Hoptman, M. J., Volavka, J., Weiss, E. M., Czobor, P., Szeszko, P. R., Gerig, G., et al. (2005). Quantitative MRI measures of orbitofrontal cortex in patients with chronic schizophrenia or schizoaffective disorder. Psychiatry Res. 140, 133–145. doi: 10.1016/j.psychres.2005.07.004

Hoptman, M. J., Zuo, X. N., Butler, P. D., Javitt, D. C., D’Angelo, D., Mauro, C. J., et al. (2010). Amplitude of low-frequency oscillations in schizophrenia: a resting state fMRI study. Schizophr. Res. 117, 13–20. doi: 10.1016/j.schres.2009.09.030

Huang, X. Q., Lui, S., Deng, W., Chan, R. C. K., Wu, Q. Z., Jiang, L. J., et al. (2010). Localization of cerebral functional deficits in treatment-naive, first-episode schizophrenia using resting-state fMRI. Neuroimage 49, 2901–2906. doi: 10.1016/j.neuroimage.2009.11.072

Kegeles, L. S., Abi-Dargham, A., Franklin, W. G., Gil, R., Cooper, T. B., Silbstein, M., et al. (2010). Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch. Gen. Psychiatry 67, 231–239. doi: 10.1001/archgenpsychiatry.2010.10

Kim, J. J., Crespo-Facorro, B., Andreasen, N. C., O’Leary, D. S., and Magnotta, V. (2000). Regional temporal abnormalities in schizophrenia: a quantitative gray matter volume and cortical surface size study. Neuroimage 11:S197. doi: 10.1016/S1053-8119(00)01930-3

Kiviniemi, V., Kantola, J. H., Jauhiainen, J., Hyvarinen, A., and Tervonen, O. (2003). Independent component analysis of nondeterministic fMRI signal sources. Neuroimage 19, 253–260.

Koolschijn, P. C., Van Haren, N. E., Cahn, W., Schnack, H. G., Jansen, J., Klumpers, F., et al. (2010). Hippocampal volume change in schizophrenia. J. Clin. Psychiatry 71, 737–744.

Kraguljac, N. V., White, D. M., Gil, R., Cooper, T. B., Silbstein, M., et al. (2010). Enhanced Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium. Biol. Psychiatry 84, 644–654. doi: 10.1016/j.biopsych.2010.04.023

Kubicki, M., Shenton, M. E., Salisbury, D. F., McFarland, J., and Lipska, B. K. (2004). Effects of chronic haloperidol and clozapine treatment on neurogenesis in the adult rat hippocampus. Neuropsychopharmacology 29, 769–780. doi: 10.1016/j.biopsych.2002.12.006

Kuo, S. S., and Pogue-Geile, M. F. (2019). Variation in fourteen brain structure volumes in schizophrenia: a comprehensive meta-analysis of 246 studies. Neurosci. Biobehav. Rev. 98, 85–94.
Lacerda, A. L. T., Hardan, A. Y., Yorbik, O., Vemulpalli, M., Prasad, K. M., and Keshavan, M. S. (2007). Morphology of the orbitofrontal cortex in first-episode schizophrenia: relationship with negative symptomatology. Prog. Neuropsychopharmacol. Biol. Psychiatry 31, 510–516. doi: 10.1016/j.pnpbp.2007.11.022

Lang, P. J., Bradley, M. M., Fitzsimmons, J. R., Cutibbert, B. N., Scott, J. D., Moulder, B., et al. (2010). Emotional arousal and activation of the visual cortex: an fMRI analysis. Psychophysiology 35, 199–210. doi: 10.1111/j.1469-8986.2009.01316-1

Lawrie, S. M., Buechel, C., Whalley, H. C., Frith, C. D., Friston, K. J., and Johnstone, E. C. (2002). Reduced frontotemporal functional connectivity in schizophrenia associated with auditory hallucinations. Biol. Psychiatry 51, 1008–1011. doi: 10.1016/S0006-3223(02)01316-1

Lee, C. U., Shenton, M. E., Salisbur, D. F., Kasai, K., Onitsuka, T., Dickey, C. C., et al. (2015). Fusiform gyrus volume reduction in first-episode schizophrenia: a magnetic resonance imaging study. Arch. Gen. Psychiatry 59, 775–781. doi: 10.1001/archpsyc.99.7.775

Lee, S. H., Niznikiewicz, M., Asami, T., Otsuka, T., Salisbur, D. F., Shenton, M. E., et al. (2015). Initial and progressive gray matter abnormalities in insular Gyrus and temporal pole in first-episode schizophrenia contrasted with first-episode affective psychosis. Schizophr. Bull. 42, 790–801. doi: 10.1093/schbul/sbv177

Lesh, T. A., Tanase, C., Geib, B. R., Niendam, T. A., Yoon, H. J., Minzenberg, M. J., et al. (2005). Increase in gray matter and decrease in white matter associated with short-term atypical antipsychotic treatment. Schizophr. Res. 80, 29–39. doi: 10.1016/j.schres.2007.05.012

Lins, K., Land, N., Nopoulos, P., Ho, B. C., and Andreassen, N. (2005). Effects of atypical and typical neuroleptics on anterior cingulate volume in schizophrenia. Schizophr. Res. 80, 73–84. doi: 10.1016/j.schres.2005.6.022

McClure, R. K., Carew, K., Greeter, S., Maushauer, E., Steen, G., and Weinberger, D. R. (2008). Absence of regional brain volume change in schizophrenia associated with short-term atypical antipsychotic treatment. Schizophr. Res. 98, 2013. doi: 10.1016/j.schres.2007.05.012

Morgan, C., Lappin, J., Heslin, M., Donoghue, K., Lomas, B., Reininghaus, U., et al. (2014). Reappraising the long-term course and outcome of psychotic disorders: the AESOP-10 study. Psychol. Med. 44, 2713–2726. doi: 10.1017/S0033291714000282

Nakamura, M., Nestor, P. G., Levitt, J. J., Cohen, A. S., Kawashima, T., Shenton, M. E., et al. (2008). Orbitofrontal volume deficit in schizophrenia and thought disorder. Brain 131, 180–195. doi: 10.1093/brain/awn265

Onitsuka, T., Mccarley, R. W., Kuroki, N., Dickey, C. C., Kubicki, M., Demeo, S. S., et al. (2007). Occipital lobe gray matter volume in male patients with chronic schizophrenia: a quantitative MRI Study. Schizophr. Res. 92, 197–206. doi: 10.1016/j.schres.2007.01.027

Pinacamacho, L., Reynejiás, A., Janssen, J., Bioué, M., Gonzalezpinto, A., Arango, C., et al. (2016). Age at first episode modulates diagnosis-related structural brain abnormalities in psychosis. Schizophr. Bull. 42, 344–357. doi: 10.1093/schbul/sbv128

Qing, Z., and Gong, G. (2016). Size matters to function: brain volume correlates with intrinsic brain activity across healthy individuals. Neuroimage 139, 271–278. doi: 10.1016/j.neuroimage.2016.06.046

Radua, J., Borgwardt, S., Crescini, A., Mataix-Cols, D., Meyer-Lindenberg, A., Mgeure, P. K., et al. (2012). Multimodal meta-analysis of structural and functional brain changes in first episode psychosis and the effects of antipsychotic medication. Neurosci. Biobehav. Rev. 36, 2353–2353. doi: 10.1016/j.nbi.2012.07.012

Velthorst, E., Fett, A. J., Reichenberg, A., Perlman, G., Van Os, J., Bromet, E. J., et al. (2017). The 20-year longitudinal trajectories of social functioning in individuals with psychotic disorders. Am. J. Psychiatry 174, 1075–1085.

Vesa, K., Juha-Heikki, K., Jukka, J., Aapo, H. R., and Osmo, T. (2003). Independent component analysis of nondeterministic fMRI signal sources. Neuroimage 19, 253–260.

Vita, A., De Peri, L., Deste, G., Barlati, S., and Sacchetti, E. (2015). The effect of antipsychotic treatment on cortical gray matter changes in Schizophrenia: Does the Class Matter? A Meta-analysis and Meta-regression of Longitudinal Magnetic Resonance Imaging Studies. Biol. Psychiatry 78, 403–412.

Vita, A., De Peri, L., Deste, G., and Sacchetti, E. (2012). Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies. Transl. Psychiatry 2:e190.

Vineskos, A. N., Mulsant, B. H., Dickie, E. W., Neufeld, N. H., Rothschild, A. J., Whyte, E. M., et al. (2020). Effects of antipsychotic medication on brain structure in patients with major depressive disorder and psychotic features: neuroimaging findings in the context of a randomized placebo-controlled clinical trial. JAMA Psychiatry 77, 674–683.

Wenting, R., Su, L., Wei, D., Fei, L., Mingli, L., Xiaoqi, H., et al. (2013). Anatomical and functional brain abnormalities in drug-naive first-episode schizophrenia. Am. J. Psychiatry 170, 1308–1316.

Wright, I. C., Rabe-Hesketh, S., Woodruff, P. W., David, A. S., Murray, R. M., and Bullmore, E. T. (2000). Meta-analysis of regional brain volumes in schizophrenia. Am. J. Psychiatry 157, 16–25.

Xu, Y., Zhuo, C., Qin, W., Zhu, J., and Yu, C. (2015). Altered spontaneous brain activity in schizophrenia: a meta-analysis and a large-sample study. Biomed Res. Int. 2015:204628.

Yang, C., Tang, J., Liu, N., Yao, L., Xu, M., Sun, H., et al. (2021). The effects of antipsychotic treatment on the brain of patients with first-episode schizophrenia: a selective review of longitudinal.
Chen et al. A Real-World Observation

MRI Studies. Front. Psychiatry 12:593703. doi: 10.3389/fpsyt.2021.593703
Zang, Y. F., He, Y., Zhu, C. Z., Cao, Q. J., Sui, M. Q., Liang, M., et al. (2007). Altered baseline brain activity in children with ADHD revealed by resting-state functional MRI. Brain Dev. 29, 83–91.
Zhang, D., and Raichle, M. (2010). Disease and the brain’s dark energy. Nat. Rev. Neuro 6, 15–28.
Zhou, Y., Liang, M., Jiang, T., Tian, L., Liu, Y., Liu, Z., et al. (2007). Functional dysconnectivity of the dorsolateral prefrontal cortex in first-episode schizophrenia using resting-state fMRI. Neurosci. Lett. 417, 297–302.
Zhou, Y., Wang, K., Liu, Y., Song, M., Song, S. W., and Jiang, T. (2010). Spontaneous brain activity observed with functional magnetic resonance imaging as a potential biomarker in neuropsychiatric disorders. Cogn. Neurodyn. 4, 275–294.
Zhuo, C., Zhu, J., Qin, W., Qu, H., Ma, X., Tian, H., et al. (2014). Functional connectivity density alterations in schizophrenia. Front. Behav. Neurosci. 8:404. doi: 10.3389/fnbeh.2014.00404

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Chen, Womer, Feng, Zhang, Zhang, Duan, Chang, Yin, Jiang, Wei, Wei, and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.